Ziihera Disease Interactions
There are 3 disease interactions with Ziihera (zanidatamab).
Zanidatamab (applies to Ziihera) heart disease
Moderate Potential Hazard, Moderate plausibility.
Zanidatamab can cause decreases in left ventricular ejection fraction (LVEF). Safety has not been established in patients with baseline ejection fraction below 50%. LVEF should be assessed before starting zanidatamab and regularly during therapy.
Zanidatamab (applies to Ziihera) liver disease
Moderate Potential Hazard, Moderate plausibility.
The effect of moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN] and any AST) or severe (total bilirubin greater than 3 x ULN and any AST) liver dysfunction on the pharmacokinetics of zanidatamab is unknown.
Zanidatamab (applies to Ziihera) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The effect of severe renal dysfunction (estimated GFR 15 to 29 mL/min) or end-stage renal disease (estimated GFR less than 15 mL/min) with or without hemodialysis on the pharmacokinetics of zanidatamab is unknown.
Switch to professional interaction data
Ziihera drug interactions
There are 92 drug interactions with Ziihera (zanidatamab).
Report options
More about Ziihera (zanidatamab)
- Ziihera consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Pemigatinib
Pemigatinib systemic is used for cholangiocarcinoma, myeloid/lymphoid neoplasms
Ivosidenib
Ivosidenib systemic is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
